{
  "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "docSlug": "5062b9a9257606648ea145bccd66e04d",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 41,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 24,
  "notes": "The slide presents a clinical trial snapshot including patient eligibility criteria and a breakdown of patient enrollment by dose cohort.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/30",
  "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "deckJsonHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json",
  "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.55,
        "x": 0.4,
        "y": 0.7
      },
      "kind": "disclaimer",
      "text": "CNS, central nervous system; DLTs, dose-limiting toxicities; mg, milligram; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; PK, pharmacokinetics; QD, once daily; RP2D, recommended phase 2 dose; ROS1+, ROS1-positive; TKI, tyrosine kinase inhibitor.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35cefdcb-a9d4-4da7-94b0-b512ae5dec92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "list",
      "text": "OBJECTIVES: Selection of RP2D and MTD; Overall safety and tolerability; PK characterization; Preliminary antitumor activity; Intracranial activity.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a3b5308-9d8a-4cad-9b8c-6fb2767b0670",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "PATIENT POPULATION: Advanced solid tumors harboring ROS1 fusions; ≥ 1 prior ROS1 TKI; No limit to prior chemo/immuno; Excluded concurrent drivers; Evaluable but non-measurable allowed.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb212d83-35c1-43df-b95c-b3bbb0161881",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "PHASE 1 DOSE-ESCALATION. Phase 1 enrollment completed August 2023: Updated data to be presented at a medical meeting in 2024",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7af0ebae-a3b3-4976-99b1-29f71256e941",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.55,
        "x": 0.4,
        "y": 0.3
      },
      "kind": "table",
      "text": "NVL-520 Dose Cohorts enrollment table showing N=35 total treated population across 25mg, 50mg, 75mg, 100mg, 125mg cohorts.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa2571b0-2ecf-44ef-a677-1b710bd07c46",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ARROS-1: A Global First-in-Human Phase 1/2 Clinical Trial of NVL-520 in Advanced ROS1-Positive NSCLC and Other Solid Tumors (NCT05118789)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d7e9679-be65-4d44-a873-a37772b02106",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}